Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Placenta-derived mesenchymal stem cells versus secretome versus standard treatment for hip osteoarthritis
IRCT20250721066581N1Phase 2Completed
- Sponsor
- Vira cell company
- Start
- May 2025
- Modality
- Small Molecules, Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of placenta-derived mesenchymal stem cells and naproxen in hip osteoarthritis (3 arms), sponsored by Vira cell company. Primary endpoints: Hip Harris Score improvement, Visual analog scale pain change and 3 more. Started May 2025; status: completed.
02
Drugs
placenta-derived mesenchymal stem cellsnaproxen
03
Conditions
hip osteoarthritis
Beyond the preview
Go deeper on IRCT20250721066581N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250721066581N1.